{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:00:22Z","timestamp":1794412822652,"version":"4.9.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-23193-2","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T06:17:20Z","timestamp":1748931440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence of HIV drug resistance among patients experiencing first-line treatment failure in Ethiopia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5066-0758","authenticated-orcid":false,"given":"Melashu","family":"Balew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gedefaw","family":"Abeje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alemtsehay","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Getu","family":"Degu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"23193_CR1","unstructured":"World Health Organization. Fact sheet HIV drug resistance. 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance"},{"key":"23193_CR2","unstructured":"Organization WH. The HIV drug resistance report-2012. World Health Organization; 2012."},{"key":"23193_CR3","unstructured":"WorldHealthOrganization. HIV drug resistance, https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/hiv-drug-resistance#:~:text=HIV%20drug%20resistance%20is%20caused,of%20drug%2Dresistant%20virus%20strains."},{"key":"23193_CR4","doi-asserted-by":"crossref","unstructured":"Chia HX, Tan SY, Ko KC, Tan RKJ, Lim J. HIV drug resistance in Southeast Asia: prevalence, determinants, and strategic management. J Public Health Emerg. 2022;6.","DOI":"10.21037\/jphe-22-5"},{"key":"23193_CR5","unstructured":"Organization WH. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2016."},{"issue":"1","key":"23193_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12981-023-00572-6","volume":"20","author":"S SeyedAlinaghi","year":"2023","unstructured":"SeyedAlinaghi S, Afsahi AM, Moradi A, Parmoon Z, Habibi P, Mirzapour P, et al. Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review. AIDS Res Therapy. 2023;20(1):74.","journal-title":"AIDS Res Therapy"},{"key":"23193_CR7","unstructured":"WHO. HIV drug resistance 2022 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance"},{"issue":"19","key":"23193_CR8","doi-asserted-by":"publisher","first-page":"e25763","DOI":"10.1097\/MD.0000000000025763","volume":"100","author":"M Nanfuka","year":"2021","unstructured":"Nanfuka M, Forrest JI, Zhang W, Okoboi S, Birungi J, Kaleebu P, et al. Durability of non-nucleotide reverse transcriptase inhibitor-based first-line ART regimens after 7 years of treatment in rural Uganda: a prospective cohort study. Medicine. 2021;100(19):e25763.","journal-title":"Medicine"},{"key":"23193_CR9","doi-asserted-by":"publisher","first-page":"1133407","DOI":"10.3389\/fmicb.2023.1133407","volume":"14","author":"A Temereanca","year":"2023","unstructured":"Temereanca A, Ruta S. Strategies to overcome HIV drug resistance-current and future perspectives. Front Microbiol. 2023;14:1133407.","journal-title":"Front Microbiol"},{"key":"23193_CR10","unstructured":"WHO. World Health Organization. Global action plan on HIV drug resistance. 2021."},{"issue":"03","key":"23193_CR11","first-page":"65","volume":"9","author":"R-H Kang","year":"2020","unstructured":"Kang R-H, Liang S-J, Ma Y-L, Liang S, Xiao L, Zhang X-H, et al. Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017. Infect Dis Poverty. 2020;9(03):65\u201373.","journal-title":"Infect Dis Poverty"},{"key":"23193_CR12","unstructured":"Hamers RL. Drug-resistant HIV-1 in sub-Saharan Africa - Research Explorer. https:\/\/pure.uva.nl\/ws\/files\/2266065\/117277_thesis.pdf"},{"issue":"37","key":"23193_CR13","doi-asserted-by":"publisher","first-page":"e21661","DOI":"10.1097\/MD.0000000000021661","volume":"99","author":"MR Jordan","year":"2020","unstructured":"Jordan MR, Hamunime N, Bikinesi L, Sawadogo S, Agolory S, Shiningavamwe AN, et al. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine. 2020;99(37):e21661.","journal-title":"Medicine"},{"key":"23193_CR14","doi-asserted-by":"publisher","first-page":"115628","DOI":"10.1016\/j.socscimed.2022.115628","volume":"317","author":"B Taverne","year":"2023","unstructured":"Taverne B, Laborde-Balen G, Sow K, Ndiaye NB, Diop K. Treatment success or failure in children and adolescents born with HIV in rural Senegal: an anthropological perspective. Soc Sci Med. 2023;317:115628.","journal-title":"Soc Sci Med"},{"key":"23193_CR15","doi-asserted-by":"crossref","unstructured":"Ayalew MB, Kumilachew D, Belay A, Getu S, Teju D, Endale D et al. First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia. HIV\/AIDS-Research and Palliative Care. 2016:141-6.","DOI":"10.2147\/HIV.S112048"},{"key":"23193_CR16","doi-asserted-by":"crossref","unstructured":"Pennings PS. HIV drug resistance: problems and perspectives. Infect Disease Rep. 2013;5(Suppl 1).","DOI":"10.4081\/idr.2013.s1.e5"},{"key":"23193_CR17","unstructured":"World Health Organization. HIV statistics, globally and by WHO region. 2023. https:\/\/cdn.who.int\/media\/docs\/default-source\/hq-hiv-hepatitis-and-stis-library\/j0294-who-hiv-epi-factsheet-v7.pdf"},{"issue":"10","key":"23193_CR18","doi-asserted-by":"publisher","first-page":"e0276730","DOI":"10.1371\/journal.pone.0276730","volume":"17","author":"CI Penda","year":"2022","unstructured":"Penda CI, Moukoko Mbonjo M, Fokam J, Djeuda ABD, Grace N, Ateba Ndongo F, et al. Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon. PLoS ONE. 2022;17(10):e0276730.","journal-title":"PLoS ONE"},{"key":"23193_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-6405-11-9","volume":"11","author":"AS Hassan","year":"2014","unstructured":"Hassan AS, Nabwera HM, Mwaringa SM, Obonyo CA, Sanders EJ, Rinke de Wit TF, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. AIDS Res Therapy. 2014;11:1\u201312.","journal-title":"AIDS Res Therapy"},{"issue":"8","key":"23193_CR20","doi-asserted-by":"publisher","first-page":"e0236156","DOI":"10.1371\/journal.pone.0236156","volume":"15","author":"S Miti","year":"2020","unstructured":"Miti S, Handema R, Mulenga L, Mwansa JK, Abrams E, Frimpong C, et al. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia. PLoS ONE. 2020;15(8):e0236156.","journal-title":"PLoS ONE"},{"key":"23193_CR21","unstructured":"Fa MOH-E. HIV\/AIDS National Strategic Plan (NSP) for Ethiopia 2021\u20132025. Available at: https:\/\/www.prepwatch.org\/wp-content\/uploads\/2022\/07\/Ethiopia-HIVAIDS-National-Strategic-Plan-2021-25.pdf"},{"key":"23193_CR22","unstructured":"UNAIDS. Country factsheets, Ethiopia. Available at: https:\/\/www.unaids.org\/en\/regionscountries\/countries\/ethiopia. 2023."},{"key":"23193_CR23","unstructured":"MinistryofHealthEthiopia. Guideline for HIV care\/ART clinical mentoring in Ethiopia 2022."},{"issue":"2suppl","key":"23193_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/135965350801302S01","volume":"13","author":"WE Abegaz","year":"2008","unstructured":"Abegaz WE, Grossman Z, Wolday D, Ram D, Kaplan J, Sibide K, et al. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in addis Ababa, Ethiopia. Antivir Ther. 2008;13(2suppl):89\u201394.","journal-title":"Antivir Ther"},{"key":"23193_CR25","doi-asserted-by":"crossref","unstructured":"Tachbele E, Kyobe S, Katabazi FA, Kigozi E, Mwesigwa S, Joloba M et al. Genetic diversity and acquired drug resistance mutations detected by deep sequencing in virologic failures among antiretroviral treatment experienced human immunodeficiency Virus-1 patients in a pastoralist region of Ethiopia. Infect Drug Resist. 2021:4833\u201347.","DOI":"10.2147\/IDR.S337485"},{"key":"23193_CR26","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Higgins JP, Altman DG, Group CSM. Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions. 2019:241\u2013\u200984.","DOI":"10.1002\/9781119536604.ch10"},{"key":"23193_CR27","unstructured":"Aromataris E, Munn Z. JBI, Manual for Evidence Synthesis JBI. 2020 [Available from: https:\/\/synthesismanual.jbi.global. https:\/\/doi.org\/10.46658. JBIMES-20-01."},{"key":"23193_CR28","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"issue":"2","key":"23193_CR29","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1002\/cl2.1229","volume":"18","author":"K Saif-Ur\u2010Rahman","year":"2022","unstructured":"Saif-Ur\u2010Rahman K, Hasan M, Hossain S, Anwar I, Hirakawa Y, Yatsuya H. Prioritization and sequential exclusion of articles in systematic reviews. Campbell Syst Reviews. 2022;18(2):e1229.","journal-title":"Campbell Syst Reviews"},{"issue":"1","key":"23193_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/bph.16100","volume":"181","author":"K Kolaski","year":"2024","unstructured":"Kolaski K, Logan LR, Ioannidis JP. Guidance to best tools and practices for systematic reviews. Br J Pharmacol. 2024;181(1):180\u2013210.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"23193_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1469-0691.12494","volume":"20","author":"W Melsen","year":"2014","unstructured":"Melsen W, Bootsma M, Rovers M, Bonten M. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20(2):123\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"23193_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/bjsports-2021-103987","volume":"56","author":"CL Ardern","year":"2022","unstructured":"Ardern CL, B\u00fcttner F, Andrade R, Weir A, Ashe MC, Holden S, et al. Implementing the 27 PRISMA 2020 statement items for systematic reviews in the sport and exercise medicine, musculoskeletal rehabilitation and sports science fields: the persist (implementing Prisma in exercise, rehabilitation, sport medicine and sports science) guidance. Br J Sports Med. 2022;56(4):175\u201395.","journal-title":"Br J Sports Med"},{"key":"23193_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jgar.2022.07.019","volume":"30","author":"Y Getaneh","year":"2022","unstructured":"Getaneh Y, He Q, Rashid A, Kassa D, kang L, Yi F, et al. Evaluation of HIV-1 drug resistance among patients failing first-line antiretroviral therapy in Ethiopia. J Global Antimicrob Resist. 2022;30:418\u201327.","journal-title":"J Global Antimicrob Resist"},{"issue":"5","key":"23193_CR34","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/QAI.0000000000002908","volume":"89","author":"DA Arimide","year":"2022","unstructured":"Arimide DA, Amogne MD, Kebede Y, Balcha TT, Adugna F, Ramos A, et al. High level of HIV drug resistance and virologic nonsuppression among female sex workers in Ethiopia: a nationwide cross-sectional study. JAIDS J Acquir Immune Defic Syndr. 2022;89(5):566\u201374.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"23193_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-14-181","volume":"14","author":"A Abdissa","year":"2014","unstructured":"Abdissa A, Yilma D, Fonager J, Audelin AM, Christensen LH, Olsen MF, et al. Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infect Dis. 2014;14:1\u20137.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"23193_CR36","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.3390\/biomedicines11082293","volume":"11","author":"Y Getaneh","year":"2023","unstructured":"Getaneh Y, Getnet F, Ning F, Rashid A, Liao L, Yi F, et al. HIV-1 disease progression and drug resistance mutations among children on First-Line antiretroviral therapy in Ethiopia. Biomedicines. 2023;11(8):2293.","journal-title":"Biomedicines"},{"issue":"10","key":"23193_CR37","doi-asserted-by":"publisher","first-page":"e0141318","DOI":"10.1371\/journal.pone.0141318","volume":"10","author":"A Mulu","year":"2015","unstructured":"Mulu A, Maier M, Liebert UG. Low incidence of HIV-1\u00a0C acquired drug resistance 10 years after roll-out of antiretroviral therapy in Ethiopia: a prospective cohort study. PLoS ONE. 2015;10(10):e0141318.","journal-title":"PLoS ONE"},{"issue":"10","key":"23193_CR38","doi-asserted-by":"publisher","first-page":"e0186619","DOI":"10.1371\/journal.pone.0186619","volume":"12","author":"A Mulu","year":"2017","unstructured":"Mulu A, Maier M, Liebert UG. Upward trends of acquired drug resistances in Ethiopian HIV-1\u00a0C isolates: A decade longitudinal study. PLoS ONE. 2017;12(10):e0186619.","journal-title":"PLoS ONE"},{"key":"23193_CR39","doi-asserted-by":"crossref","unstructured":"Reepalu A, Arimide DA, Balcha TT, Yeba H, Zewdu A, Medstrand P, et al. editors. Drug resistance in HIV-positive adults during the initial year of antiretroviral treatment at Ethiopian health centers. Open Forum Infect Dis; 2021: Oxford University Press US.","DOI":"10.1093\/ofid\/ofab106"},{"issue":"2","key":"23193_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/v10020060","volume":"10","author":"BT Tadesse","year":"2018","unstructured":"Tadesse BT, Kinloch NN, Baraki B, Lapointe HR, Cobarrubias KD, Brockman MA, et al. High levels of dual-class drug resistance in HIV-infected children failing first-line antiretroviral therapy in Southern Ethiopia. Viruses. 2018;10(2):60.","journal-title":"Viruses"},{"key":"23193_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-019-4196-8","volume":"19","author":"NF Telele","year":"2019","unstructured":"Telele NF, Kalu AW, Gebre-Selassie S, Fekade D, Marrone G, Grossmann S, et al. A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort. BMC Infect Dis. 2019;19:1\u201310.","journal-title":"BMC Infect Dis"},{"key":"23193_CR42","doi-asserted-by":"crossref","unstructured":"Zuo L, Liu K, Liu H, Hu Y, Zhang Z, Qin J et al. Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001\u20132017). EClinicalMedicine. 2020;18.","DOI":"10.1016\/j.eclinm.2019.100238"},{"issue":"6","key":"23193_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000497036","volume":"61","author":"M Mohraz","year":"2019","unstructured":"Mohraz M, Tayeri K, Namdari Tabar H, Bayat Jozani Z, Sadeghi L, SeyedAlinaghi S, et al. Evaluation of acquired HIV drug resistance among people living with HIV who have taken antiretroviral therapy for 9\u201315 months in 14 triangular clinics in Iran, 2015\u20132016. Intervirology. 2019;61(6):292\u2013300.","journal-title":"Intervirology"},{"issue":"1","key":"23193_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12879-023-08916-3","volume":"24","author":"H Mirzaei","year":"2024","unstructured":"Mirzaei H, Eybpoosh S, Mehrabi F, Shojaei MR, Mirzazadeh A, Khezri M, et al. Prevalence of acquired and transmitted HIV drug resistance in Iran: a systematic review and meta-analysis. BMC Infect Dis. 2024;24(1):29.","journal-title":"BMC Infect Dis"},{"key":"23193_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.eclinm.2018.06.005","volume":"1","author":"GF Tchouwa","year":"2018","unstructured":"Tchouwa GF, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C, et al. Nationwide estimates of viral load suppression and acquired HIV drug resistance in Cameroon. EClinicalMedicine. 2018;1:21\u20137.","journal-title":"EClinicalMedicine"},{"key":"23193_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eclinm.2019.03.013","volume":"9","author":"N Ngo-Giang-Huong","year":"2019","unstructured":"Ngo-Giang-Huong N, Aghokeng AF. HIV drug resistance in resource-limited countries: threat for HIV elimination. EClinicalMedicine. 2019;9:3\u20134.","journal-title":"EClinicalMedicine"},{"issue":"4","key":"23193_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3851\/IMP2709","volume":"19","author":"HB Krentz","year":"2014","unstructured":"Krentz HB, Ko K, Beckthold B, Gill MJ. The cost of antiretroviral drug resistance in HIV-positive patients. Antivir Ther. 2014;19(4):341\u20138.","journal-title":"Antivir Ther"},{"key":"23193_CR48","unstructured":"WHO. HIV drug resistance \u2013 brief report 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240086319"},{"issue":"10","key":"23193_CR49","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/jac\/dkz272","volume":"74","author":"G Barabona","year":"2019","unstructured":"Barabona G, Mahiti M, Masoud S, Mbelele P, Mgunya AS, Minja L, et al. Pre-treatment and acquired HIV drug resistance in Dar Es Salaam, Tanzania in the era of Tenofovir and routine viral load monitoring. J Antimicrob Chemother. 2019;74(10):3016\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"23193_CR50","doi-asserted-by":"publisher","first-page":"e0232649","DOI":"10.1371\/journal.pone.0232649","volume":"15","author":"SR Mziray","year":"2020","unstructured":"Mziray SR, Kumburu HH, Assey HB, Sonda TB, Mahande MJ, Msuya SE, et al. Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania. PLoS ONE. 2020;15(9):e0232649.","journal-title":"PLoS ONE"},{"key":"23193_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-021-00393-5","volume":"18","author":"B Chimukangara","year":"2021","unstructured":"Chimukangara B, Lessells RJ, Singh L, Grigalionyte I, Yende-Zuma N, Adams R, et al. Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa. AIDS Res Therapy. 2021;18:1\u20138.","journal-title":"AIDS Res Therapy"},{"key":"23193_CR52","doi-asserted-by":"publisher","first-page":"1338191","DOI":"10.3389\/fmicb.2024.1338191","volume":"15","author":"PT Mokgethi","year":"2024","unstructured":"Mokgethi PT, Choga WT, Maruapula D, Moraka NO, Seatla KK, Bareng OT, et al. High prevalence of pre-treatment and acquired HIV-1 drug resistance mutations among non-citizens living with HIV in Botswana. Front Microbiol. 2024;15:1338191.","journal-title":"Front Microbiol"},{"issue":"9","key":"23193_CR53","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1089\/aid.2019.0279","volume":"36","author":"F Segujja","year":"2020","unstructured":"Segujja F, Omooja J, Lunkuse S, Nanyonjo M, Nabirye SE, Nassolo F, et al. High levels of acquired HIV drug resistance following virological nonsuppression in HIV-Infected women from a High-Risk cohort in Uganda. AIDS Res Hum Retroviruses. 2020;36(9):782\u201391.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"23193_CR54","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1093\/cid\/ciu590","volume":"59","author":"H Liu","year":"2014","unstructured":"Liu H, Ma Y, Su Y, Smith MK, Liu Y, Jin Y, et al. Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis. Clin Infect Dis. 2014;59(10):1495\u2013502.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"23193_CR55","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/aid.2013.0262","volume":"30","author":"SJ Snedecor","year":"2014","unstructured":"Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, et al. Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis. AIDS Res Hum Retroviruses. 2014;30(8):753\u201368.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"23193_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fmicb.2019.00369","volume":"10","author":"KM Gibson","year":"2019","unstructured":"Gibson KM, Steiner MC, Kassaye S, Maldarelli F, Grossman Z, P\u00e9rez-Losada M, et al. A 28-year history of HIV-1 drug resistance and transmission in Washington, DC. Front Microbiol. 2019;10:369.","journal-title":"Front Microbiol"},{"key":"23193_CR57","unstructured":"WHO, Antimicrobial resistance WHOfactsheet. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance"},{"issue":"1","key":"23193_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4314\/ejhs.v27i1.1S","volume":"27","author":"G Barnabas","year":"2017","unstructured":"Barnabas G, Sibhatu MK, Berhane Y. Antiretroviral therapy program in Ethiopia benefits from virology treatment monitoring. Ethiop J Health Sci. 2017;27(1):1\u20132.","journal-title":"Ethiop J Health Sci"},{"issue":"6","key":"23193_CR59","doi-asserted-by":"publisher","first-page":"490","DOI":"10.5001\/omj.2019.91","volume":"34","author":"O Al-Omairi","year":"2019","unstructured":"Al-Omairi O, Elgalib A, Al Kindi H. HIV drug resistance among patients failing therapy at a tertiary center in Oman: A case record review. Oman Med J. 2019;34(6):490.","journal-title":"Oman Med J"},{"issue":"4","key":"23193_CR60","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jval.2014.12.014","volume":"18","author":"MCP Ramos","year":"2015","unstructured":"Ramos MCP, Barton P, Jowett S, Sutton AJ. A systematic review of research guidelines in decision-analytic modeling. Value Health. 2015;18(4):512\u201329.","journal-title":"Value Health"},{"key":"23193_CR61","unstructured":"Ebonyi AO, Okpokwu J, Rawizza H, Chebu P, Chaplin B, Hamel D, et al. editors. Pretreatment and acquired drug resistance in HIV-1 infected children in Jos, Nigeria. Open forum infectious diseases. Oxford University Press; 2024."},{"issue":"7","key":"23193_CR62","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/INF.0000000000001843","volume":"37","author":"B Corrigan","year":"2018","unstructured":"Corrigan B, Mukui I, Mulenga L, Mthethwa N, Letsie M, Bruno S, et al. Characteristics of treatment-experienced HIV-infected African children and adolescents initiating Darunavir and\/or etravirine-based antiretroviral treatment. Pediatr Infect Dis J. 2018;37(7):669\u201372.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"23193_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jac\/dkw463","volume":"72","author":"R Boerma","year":"2017","unstructured":"Boerma R, Sigaloff K, Akanmu A, Inzaule S, van Boele M, Rinke de Wit T, et al. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(2):365\u201371.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"23193_CR64","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/cid\/cix698","volume":"65","author":"MR Jordan","year":"2017","unstructured":"Jordan MR, Penazzato M, Cournil A, Vubil A, Jani I, Hunt G, et al. Human immunodeficiency virus (HIV) drug resistance in African infants and young children newly diagnosed with HIV: a multicountry analysis. Clin Infect Dis. 2017;65(12):2018\u201325.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"23193_CR65","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.clp.2010.08.009","volume":"37","author":"PJ Weidle","year":"2010","unstructured":"Weidle PJ, Nesheim S. HIV drug resistance and mother-to-child transmission of HIV. Clin Perinatol. 2010;37(4):825\u201342.","journal-title":"Clin Perinatol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23193-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-23193-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23193-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T07:03:22Z","timestamp":1748934202000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-23193-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23193"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-23193-2","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2059"}}